Results 131 to 140 of about 102,316 (180)

[Progress on the development of the SARS-CoV-2 vaccine and antibody drugs]. [PDF]

open access: yesSheng Wu Yi Xue Gong Cheng Xue Za Zhi, 2022
Xu S, Tang D.
europepmc   +1 more source

用ELISA进行AB型体液与A和B型混和体液的鉴别

open access: yesZhongshan Daxue xuebao. Yixue kexue ban, 1989
AB型人体液中,在同一血型物质分子上,同时含有A和B抗原活性。我们应用这一研究结果,用酶联免疫吸附法(ELISA)来进行AB型体液(斑)与A和B型混和体液(斑)的血型测定和鉴别。用单克隆抗A或抗B抗体进行包被,通过用人抗A、人抗B抗体和酶标抗人IgM来进行A和B血型物质的定量分析。用这种方法10,000倍稀释的体液仍能测出。AB型体液(斑),在单克隆抗A或者抗B包被板,能同时测出A和B型血型物质。然而,A和B型混和体液(斑),在相应的抗体包被板上,则只能测出相应的一种血型物质A或B。
doaj  

[Chinese expert consensus on quality control, result analysis, and reporting of anti-HLA antibody testing in allogeneic hematopoietic stem cell transplantation (2025)]. [PDF]

open access: yesZhonghua Xue Ye Xue Za Zhi
Experimental Diagnostics Group   +2 more
europepmc   +1 more source

[Characteristics of serum autoantibodies in patients with lupus nephritis and tubulointerstitial damage]. [PDF]

open access: yesBeijing Da Xue Xue Bao Yi Xue Ban, 2022
Zhang L   +6 more
europepmc   +1 more source

[Clinical characteristics and risk factors for disease progression in patients with anti-gp210 antibody-positive primary biliary cholangitis]. [PDF]

open access: yesZhonghua Gan Zang Bing Za Zhi
Ran Y   +10 more
europepmc   +1 more source

[Relationship between anti-ENO1 antibody and systemic lupus erythematosus patients with retinopathy]. [PDF]

open access: yesBeijing Da Xue Xue Bao Yi Xue Ban, 2022
Zhang LQ   +8 more
europepmc   +1 more source

免疫印迹技术检测多种风湿病多肽抗体的临床价值

open access: yesZhongshan Daxue xuebao. Yixue kexue ban, 1993
本文对20例系统性红斑狼疮(SLE)、7例干燥综合征(SS)、9例类风湿关节炎(RA)、15例结缔组织病(CTD)及10名正常人用免疫印迹方法(IBT)进行了多肽抗体的检测,结果表明:抗27.776 X10~3IU、13.392 X10~3IU的抗体是SLR特征性抗体,而抗44.64 X10~3IU、46.624 X10~3IU/47.616 X10~3IU的抗体与SS密切相关,同时还提出IBT检测多肽抗体较对流免疫电泳(CIE)敏感,且能测到一些少见的抗体。
doaj  

[Clinical significance of antiphospholipid antibodies in Behcet disease with thrombosis]. [PDF]

open access: yesBeijing Da Xue Xue Bao Yi Xue Ban
Li Y, Wang H, Luo L, Li Y, Li C.
europepmc   +1 more source

Home - About - Disclaimer - Privacy